4E3N
Crystal structure of AmpC beta-lactamase in complex with a 2-trifluoromethyl-4-tetrazolyl benzene sulfonamide boronic acid inhibitor
Summary for 4E3N
Entry DOI | 10.2210/pdb4e3n/pdb |
Related | 4E3I 4E3J 4E3K 4E3L 4E3M 4E3O |
Descriptor | Beta-lactamase, [({[4-(1H-tetrazol-5-yl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]boronic acid, PHOSPHATE ION, ... (4 entities in total) |
Functional Keywords | ampc beta-lactamase, class c, cephalosporinase, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
Biological source | Escherichia coli |
Cellular location | Periplasm: P00811 |
Total number of polymer chains | 2 |
Total formula weight | 80162.90 |
Authors | Eidam, O.,Shoichet, B.K. (deposition date: 2012-03-09, release date: 2012-09-26, Last modification date: 2023-09-13) |
Primary citation | Eidam, O.,Romagnoli, C.,Dalmasso, G.,Barelier, S.,Caselli, E.,Bonnet, R.,Shoichet, B.K.,Prati, F. Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proc.Natl.Acad.Sci.USA, 109:17448-17453, 2012 Cited by PubMed Abstract: Fragment-based design was used to guide derivatization of a lead series of β-lactamase inhibitors that had heretofore resisted optimization for in vivo activity. X-ray structures of fragments overlaid with the lead suggested new, unanticipated functionality and points of attachment. Synthesis of three derivatives improved affinity over 20-fold and improved efficacy in cell culture. Crystal structures were consistent with the fragment-based design, enabling further optimization to a K(i) of 50 pM, a 500-fold improvement that required the synthesis of only six derivatives. One of these, compound 5, was tested in mice. Whereas cefotaxime alone failed to cure mice infected with β-lactamase-expressing Escherichia coli, 65% were cleared of infection when treated with a cefotaxime:5 combination. Fragment complexes offer a path around design hurdles, even for advanced molecules; the series described here may provide leads to overcome β-lactamase-based resistance, a key clinical challenge. PubMed: 23043117DOI: 10.1073/pnas.1208337109 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.49 Å) |
Structure validation
Download full validation report